Journal Publications

Export 122 results:
[ Author(Desc)] Title Type Year
Filters: Type is Journal Article  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M et al. HIV Med, 2010 Aug, Volume 11, Issue 7, p.432-8, (2010)
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M et al. J Acquir Immune Defic Syndr, 2009 Nov 01, Volume 52, Issue 3, p.391-6, (2009)
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? Bansi L, Benzie A, Phillips A, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R et al. AIDS, 2008 Jan 30, Volume 22, Issue 3, p.349-56, (2008)
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). Bansi L, Geretti A, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al. J Acquir Immune Defic Syndr, 2010 Apr, Volume 53, Issue 5, p.633-9, (2010)
The impact of HIV drug resistance testing on changes to treatment. Bansi L, Smith C, Phillips A, Kirk S, Geretti A, Johnson M, Mackie N, Post F, Gazzard B, Dunn D et al. AIDS, 2011 Mar 13, Volume 25, Issue 5, p.603-10, (2011)
Virological response to initial antiretroviral regimens containing abacavir or tenofovir. Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J et al. J Infect Dis, 2009 Sep 01, Volume 200, Issue 5, p.710-4, (2009)
Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Bansi L, Hughes A, Bhagani S, Mackie N, Leen C, Levy J, Edwards S, Connolly J, Holt S, Hendry B et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2517-21, (2009)
Biomarkers to monitor safety in people on art and risk of mortality. Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M et al. J Acquir Immune Defic Syndr, 2012 May 01, Volume 60, Issue 1, p.51-8, (2012)
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Barber T, Geretti A, Anderson J, Schwenk A, Phillips A, Bansi L, Gilson R, Hill T, Walsh J, Fisher M et al. Antivir Ther, 2011, Volume 16, Issue 6, p.805-14, (2011)
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Barber T, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D and Dunn D. J Antimicrob Chemother, 2012 Apr, Volume 67, Issue 4, p.995-1000, (2012)
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. Benzie A, Bansi L, Sabin C, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M et al. AIDS, 2007 Jul 11, Volume 21, Issue 11, p.1423-30, (2007)
Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. Booth J, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar E, Turner-Stokes T, Khatib N, Das P et al. Nephrol Dial Transplant, 2016 Dec, Volume 31, Issue 12, p.2099-2107, (2016)
Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, Monforte A, Mary-Krause M, Roca B, Miro J et al. HIV Med, 2017 Jan, Volume 18, Issue 1, p.33-44, (2017)
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P et al. Haematologica, 2009 Jun, Volume 94, Issue 6, p.875-80, (2009)
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. Bulteel N, Bansi-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Sabin C and Nelson M. J Infect, 2014 Jan, Volume 68, Issue 1, p.77-84, (2014)
C
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Chilton D, Castro H, Lattimore S, Harrison L, Fearnhill E, Delpech V, Rice B, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 7, p.985-91, (2010)
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth J, van Sighem A, Kirk O, Obel N, Panos G et al. Int J Epidemiol, 2012 Apr, Volume 41, Issue 2, p.433-45, (2012)
Response to combination antiretroviral therapy: variation by age. Sabin C, Smith C, Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A et al. AIDS, 2008 Jul 31, Volume 22, Issue 12, p.1463-73, (2008)
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Murillo A, Mocroft A, Bonnet F, Clifford G, Touloumi G et al. AIDS, 2009 Sep 24, Volume 23, Issue 15, p.2029-37, (2009)
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo A, Mocroft A, Bonnet F, Clifford G, Karafoulidou A et al. Antivir Ther, 2009, Volume 14, Issue 8, p.1065-74, (2009)
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. Cozzi-Lepri A, Prosperi M, Kjær J, Dunn D, Paredes R, Sabin C, Lundgren J, Phillips A and Pillay D. PLoS One, 2011, Volume 6, Issue 11, p.e25665, (2011)
D
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer F, Van Laethem K et al. J Infect Dis, 2013 Apr 15, Volume 207, Issue 8, p.1216-20, (2013)
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro M, Günthard H, Wittkop L, Kordossis T, García F et al. J Antimicrob Chemother, 2016 May, Volume 71, Issue 5, p.1352-60, (2016)
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Dolling D, Dunn D, Geretti A and Sabin C. Clin Infect Dis, 2013 Jan, Volume 56, Issue 1, p.162-3, (2013)